A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

Popat, S.; Curioni-Fontecedro, A.; Dafni, U.; Shah, R.; O'Brien, M.; Pope, A.; Fisher, P.; Spicer, J.; Roy, A.; Gilligan, D.; Gautschi, O.; Nadal, E.; Janthur, W.D.; López Castro, R.; García Campelo, R.; Rusakiewicz, S.; Letovanec, I.; Polydoropoulou, V.; Roschitzki-Voser, H.; Ruepp, B.; Gasca-Ruchti, A.; Peters, S.; Stahel, R.A.

doi:10.1016/j.annonc.2020.09.009

A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

BACKGROUND Malignant pleural mesothelioma (MPM) is an aggressive malignancy characterized by limited treatment options and a poor prognosis. At relapse after platinum-based chemotherapy, single-agent chemotherapy is commonly used and single-arm trials of immune-checkpoint inhibitors have demonstr…